Safety and efficacy of various dosages of ocrelizumab in Japanese patients with rheumatoid arthritis with an inadequate response to methotrexate therapy: A placebo-controlled double-blind parallel-group study

Masayoshi Harigai, Yoshiya Tanaka, Shingo Maisawa, Kazuhide Tanimura, Hiroki Takahashi, Yukitomo Urata, Yasuhiko Hirabayashi, Tomonori Ishii, Hiroshi Fujii, Takayuki Sumida, Chihiro Terai, Ryutaro Matsumura, Makoto Sueishi, Kazuhiko Yamamoto, Akio Yamada, Daitaro Kurosaka, Akio Mimori, Yusuke Miwa, Masataka Kuwana, Shinichi KawaiYoshiaki Ishigatsubo, Kazunori Sugimoto, Noriyoshi Ogawa, Toshiaki Miyamoto, Shigenori Tamaki, Motokazu Kai, Daisuke Kawabata, Toshio Tanaka, Masaaki Inaba, Shunichi Kumagai, Akio Morinobu, Yasushi Miura, Hajime Sano, Naoki Kashihara, Yoshitaka Morita, Kazuhiko Ezawa, Yuji Yamanishi, Masanori Kawashima, Seizo Yamana, Mitsuhiro Iwahashi, Hiroaki Dobashi, Kiyoshi Takasugi, Takahiko Horiuchi, Eiichi Suematsu, Takaaki Fukuda, Katsumi Eguchi, Atsushi Kawakami

Research output: Contribution to journalArticlepeer-review

25 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Safety and efficacy of various dosages of ocrelizumab in Japanese patients with rheumatoid arthritis with an inadequate response to methotrexate therapy: A placebo-controlled double-blind parallel-group study'. Together they form a unique fingerprint.

Nursing and Health Professions

Pharmacology, Toxicology and Pharmaceutical Science